{"protocolSection":{"identificationModule":{"nctId":"NCT03822351","orgStudyIdInfo":{"id":"D9108C00001"},"secondaryIdInfos":[{"id":"2018-002931-35","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"MedImmune LLC","class":"INDUSTRY"},"briefTitle":"Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC","officialTitle":"A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)","acronym":"COAST"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"COMPLETED","startDateStruct":{"date":"2018-12-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-07-18","type":"ACTUAL"},"completionDateStruct":{"date":"2023-07-18","type":"ACTUAL"},"studyFirstSubmitDate":"2018-12-10","studyFirstSubmitQcDate":"2019-01-29","studyFirstPostDateStruct":{"date":"2019-01-30","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-07-01","resultsFirstSubmitQcDate":"2024-10-04","resultsFirstPostDateStruct":{"date":"2024-10-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-04","lastUpdatePostDateStruct":{"date":"2024-10-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedImmune LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.","detailedDescription":"Study D9108C00001 (COAST) is a Phase 2, open-label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Stage III Non-small Cell Lung Cancer","Unresectable"],"keywords":["Locally Advanced NSCLC","Non-small Cell Lung Cancer","Cancer","Lung","Unresectable","Stage III"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"At study onset subjects will be randomized equally to all study treatment arms open for enrollment and will remain on study treatment for up to 12 months.\n\nStudy treatment will be discontinued upon disease progression, unacceptable toxicity, or other reason. The treatment arms are Control Arm, Arm A and Arm B.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":189,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Control Arm (Durvalumab monotherapy)","type":"EXPERIMENTAL","description":"durvalumab IV","interventionNames":["Drug: Durvalumab"]},{"label":"Arm A (durvalumab + oleclumab):","type":"EXPERIMENTAL","description":"durvalumab IV and oleclumab IV","interventionNames":["Drug: Durvalumab + Oleclumab"]},{"label":"Arm B (durvalumab + monalizumab)","type":"EXPERIMENTAL","description":"durvalumab IV and monalizumab IV","interventionNames":["Drug: Durvalumab + Monalizumab"]}],"interventions":[{"type":"DRUG","name":"Durvalumab + Oleclumab","description":"Durvalumab + Oleclumab","armGroupLabels":["Arm A (durvalumab + oleclumab):"],"otherNames":["Durvalumab (MEDI-4736)","Oleclumab (MEDI-9447)"]},{"type":"DRUG","name":"Durvalumab","description":"Durvalumab","armGroupLabels":["Control Arm (Durvalumab monotherapy)"],"otherNames":["Durvalumab (MEDI-4736)"]},{"type":"DRUG","name":"Durvalumab + Monalizumab","description":"Durvalumab + Monalizumab","armGroupLabels":["Arm B (durvalumab + monalizumab)"],"otherNames":["Durvalumab (MEDI-4736)","Monalizumab (IPH2201)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"ORR was defined as the percentage of participants with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: \\>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.","timeFrame":"ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint"}],"secondaryOutcomes":[{"measure":"Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents","description":"The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events","timeFrame":"From time of signature of informed consent up to 15 months post the first dose of study treatment"},{"measure":"Presence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents","description":"The secondary endpoint of safety as assessed by the presence of Grade 3 or 4 clinical laboratory toxicities (based on NCI-CTCAE v5.0) in chemistry and hematology values","timeFrame":"From baseline up to 15 months post the first dose of study treatment"},{"measure":"Presence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents","description":"The secondary endpoint of safety as assessed by the presence of abnormal vital signs reported as adverse events","timeFrame":"From baseline up to 15 months post the first dose of study treatment"},{"measure":"Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only participants who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR","timeFrame":"Up to approximately 54 months (through the database cutoff date of 18-Jul-2023)."},{"measure":"Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"Disease control rate (DCR) was defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD (maintained for ≥ 16 weeks) based on RECIST v1.1.","timeFrame":"Up to approximately 54 months (through the database cutoff date of 18-Jul-2023)."},{"measure":"Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"PFS was defined as the time from randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first","timeFrame":"Up to approximately 54 months (through the database cutoff date of 18-Jul-2023)."},{"measure":"Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"PFS-12 was defined as the percentage of participants who were alive and progression free at 12 months after randomization.","timeFrame":"PFS rate at 12 months after randomization."},{"measure":"Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"OS was defined as the time from the date of randomization until death due to any cause.","timeFrame":"From time of randomization until death due to any cause. Assessed through the database cutoff date of 18-Jul-2023)."},{"measure":"Pharmacokinetics of Durvalumab Alone and in Combination With Novel Agents","description":"Geometric mean serum concentrations of durvalumab (μg/mL) were reported for each time point where data warrant, as appropriate.","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1"},{"measure":"Pharmacokinetics of Novel Agents in Combination With Durvalumab","description":"Geometric mean serum concentrations of oleclumab (μg/mL) and monalizumab (μg/mL) were reported for each time point where data warrant, as appropriate.","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1"},{"measure":"Presence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents","description":"ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.\n\nADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1"},{"measure":"Presence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab","description":"ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.\n\nADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1"}]},"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n1. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation\n2. Age 18 years or older\n3. Body weight ≥ 35 kg\n4. Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease\n5. Subjects must have completed, without progressing, definitive cCRT within 42 days prior to being randomized into the study\n6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy\n7. Life expectancy ≥ 12 weeks\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1\n\nMain Exclusion Criteria:\n\n1. Mixed small cell and non-small cell lung cancer histology\n2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug\n3. Prior exposure to any anti-PD1, anti-PD-L1, or anti-CTLA4 antibody for treatment of NSCLC\n4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy\n5. Subjects with a history of venous thrombosis within the past 3 months\n6. Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months\n7. Congestive heart failure\n8. Active or prior documented autoimmune or inflammatory disorders\n9. History of active primary immunodeficiency\n10. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)\n11. History of allogenic organ transplantation\n12. QTcF interval ≥ 470 ms\n13. History of another primary malignancy\n14. Concurrent enrollment in another clinical study \\[concurrent enrollment in an observational (non-interventional) clinical study or during the follow-up period of an interventional study is permitted\\]\n15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Research Site","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Research Site","city":"Sacramento","state":"California","zip":"95825","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Research Site","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Research Site","city":"West Haven","state":"Connecticut","zip":"06516","country":"United States","geoPoint":{"lat":41.27065,"lon":-72.94705}},{"facility":"Research Site","city":"Washington D.C.","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Research Site","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Research Site","city":"Winter Haven","state":"Florida","zip":"33881","country":"United States","geoPoint":{"lat":28.02224,"lon":-81.73286}},{"facility":"Research Site","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Research Site","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Research Site","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Research Site","city":"Baton Rouge","state":"Louisiana","zip":"70809","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Research Site","city":"Covington","state":"Louisiana","zip":"70433","country":"United States","geoPoint":{"lat":30.47549,"lon":-90.10042}},{"facility":"Research Site","city":"Rosedale","state":"Maryland","zip":"21237","country":"United States","geoPoint":{"lat":39.32011,"lon":-76.51552}},{"facility":"Research Site","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97227-1191","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Gettysburg","state":"Pennsylvania","zip":"17325","country":"United States","geoPoint":{"lat":39.83093,"lon":-77.2311}},{"facility":"Research Site","city":"Lancaster","state":"Pennsylvania","zip":"17601","country":"United States","geoPoint":{"lat":40.03788,"lon":-76.30551}},{"facility":"Research Site","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Research Site","city":"Sioux Falls","state":"South Dakota","zip":"57105","country":"United States","geoPoint":{"lat":43.54369,"lon":-96.72796}},{"facility":"Research Site","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Research Site","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Research Site","city":"Tyler","state":"Texas","zip":"75701","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Research Site","city":"Salt Lake City","state":"Utah","zip":"84112","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Research Site","city":"Richmond","state":"Virginia","zip":"23230","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Research Site","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"facility":"Research Site","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Research Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Montreal","state":"Quebec","zip":"H4A 3J1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Research Site","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Research Site","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Research Site","city":"Bron","zip":"69677","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"facility":"Research Site","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Research Site","city":"La Rochelle","zip":"17019","country":"France","geoPoint":{"lat":46.16308,"lon":-1.15222}},{"facility":"Research Site","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Research Site","city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Research Site","city":"Lyon","zip":"69004","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Research Site","city":"Marseille","zip":"13015","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Research Site","city":"Nice","zip":"06189","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"Research Site","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"Research Site","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Research Site","city":"Strasbourg","zip":"67065","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Research Site","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Research Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Research Site","city":"Jordan","country":"Hong Kong","geoPoint":{"lat":22.30539,"lon":114.17001}},{"facility":"Research Site","city":"Kowloon","country":"Hong Kong","geoPoint":{"lat":22.31667,"lon":114.18333}},{"facility":"Research Site","city":"Catania","zip":"95125","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Research Site","city":"Cremona","zip":"26100","country":"Italy","geoPoint":{"lat":45.13325,"lon":10.02129}},{"facility":"Research Site","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Palermo","zip":"90127","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Research Site","city":"Ravenna","zip":"48121","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"facility":"Research Site","city":"Siena","zip":"53100","country":"Italy","geoPoint":{"lat":43.31822,"lon":11.33064}},{"facility":"Research Site","city":"Gdynia","zip":"81-519","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Research Site","city":"Lodz","zip":"90-153","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Research Site","city":"Lodz","zip":"90-242","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Research Site","city":"Lisbon","zip":"1400-038","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Research Site","city":"Lisbon","zip":"1500-650","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Research Site","city":"Porto","zip":"4099-001","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Research Site","city":"Badajoz","zip":"06008","country":"Spain","geoPoint":{"lat":38.87789,"lon":-6.97061}},{"facility":"Research Site","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Castellon","zip":"12002","country":"Spain","geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"Research Site","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Research Site","city":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Research Site","city":"Chiayi City","zip":"61363","country":"Taiwan","geoPoint":{"lat":23.47917,"lon":120.44889}},{"facility":"Research Site","city":"Taichung","zip":"402","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}}]},"referencesModule":{"references":[{"pmid":"40663352","type":"DERIVED","citation":"Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial. JAMA Netw Open. 2025 Jul 1;8(7):e2518440. doi: 10.1001/jamanetworkopen.2025.18440."},{"pmid":"35452273","type":"DERIVED","citation":"Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22."}],"seeAlsoLinks":[{"label":"CSP redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9108C00001&amp;attachmentIdentifier=de7dfeb7-8334-4784-8d4a-da8d429556aa&amp;fileName=d9108c00001-csp-amendment-4_Redacted.pdf&amp;versionIdentifier="},{"label":"SAP redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9108C00001&amp;attachmentIdentifier=51d2c3e5-8514-4a79-907b-da0a3149d00c&amp;fileName=D9108C00001_Statistical_Analysis_Plan_v5_Redacted.pdf&amp;versionIdentifier="},{"label":"CSR Synopsis redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9108C00001&amp;attachmentIdentifier=f0bb70f9-6f4e-4554-b7e4-aafad3298d36&amp;fileName=d9108c00001-study-synopsis_Redacted.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The first participant was randomized into the study on 3 January 2019 and the last participant was randomized on 6 July 2020.","groups":[{"id":"FG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"FG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"FG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"62"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"30"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"32"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"24"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Not Treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group","groups":[{"id":"BG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"BG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"BG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"189"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.5","spread":"8.9"},{"groupId":"BG001","value":"63.8","spread":"9.5"},{"groupId":"BG002","value":"64.4","spread":"9.2"},{"groupId":"BG003","value":"64.6","spread":"9.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"60"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"129"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"178"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"14"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"159"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"6"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"39"}]}]},{"title":"Hong-Kong","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}]}]},{"title":"Portugal","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"53"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"71"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"ORR was defined as the percentage of participants with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: \\>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.","populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","lowerLimit":"14.3","upperLimit":"35.9"},{"groupId":"OG001","value":"35.0","lowerLimit":"23.1","upperLimit":"48.4"},{"groupId":"OG002","value":"40.3","lowerLimit":"28.1","upperLimit":"53.6"}]}]}]},{"type":"SECONDARY","title":"Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents","description":"The secondary endpoint of safety as assessed by the presence of adverse events and serious adverse events","populationDescription":"The As-treated population included all participants who receive any IP. Participants were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From time of signature of informed consent up to 15 months post the first dose of study treatment","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Participants with any TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"61"}]}]},{"title":"Participants with any serious TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"17"}]}]}]},{"type":"SECONDARY","title":"Presence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents","description":"The secondary endpoint of safety as assessed by the presence of Grade 3 or 4 clinical laboratory toxicities (based on NCI-CTCAE v5.0) in chemistry and hematology values","populationDescription":"The As-treated population included all participants who receive any IP. Participants were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline up to 15 months post the first dose of study treatment","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Participants with any Grade 3 or 4 Alanine Aminostransferase (U/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Albumin (g/dL) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Amylase (U/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"Participants with any Grade 3 or 4 Aspartate Aminotransferase (U/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Participants with any Grade 3 or 4 Creatinine (mg/dL) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Creatinine Clearance Rate (mL/min) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Gamma Glutamyl Transferase (U/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Hyperkalemia (mEq/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"Participants with any Grade 3 or 4 Hypokalemia (mEq/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Participants with any Grade 3 or 4 Hypocalcemia (corrected) (mg/dL) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Hypernatremia (mEq/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Participants with any Grade 3 or 4 Lipase (U/L) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]},{"title":"Participants with any Grade 3 or 4 Hemoglobin increased (g/dL) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Participants with any Grade 3 or 4 Lymphocyte count increased (10^3/uL) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}]}]},{"title":"Participants with any Grade 3 or 4 Platelet count decreased (10^3/uL) toxicities","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Presence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents","description":"The secondary endpoint of safety as assessed by the presence of abnormal vital signs reported as adverse events","populationDescription":"The As-treated population included all participants who receive any IP. Participants were analyzed according to the treatment they received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline up to 15 months post the first dose of study treatment","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hypotension","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"}]}]},{"title":"Palpitations","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Pyrexia","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"}]}]},{"title":"Tachycardia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"The duration from the first documentation of a subsequently confirmed OR to the first documentation of a disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first. Only participants who have achieved OR (confirmed CR or confirmed PR) will be evaluated for DoR","populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group. Only participants with an objective response were included in the DoR analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"14.1","upperLimit":"NA","comment":"The median and upper limit of 95% CI could not be calculated as they were not reached."},{"groupId":"OG001","value":"29.9","lowerLimit":"17.1","upperLimit":"NA","comment":"The upper limit of 95% CI could not be calculated as it was not reached."},{"groupId":"OG002","value":"23.0","lowerLimit":"10.2","upperLimit":"NA","comment":"The upper limit of 95% CI could not be calculated as it was not reached."}]}]}]},{"type":"SECONDARY","title":"Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"Disease control rate (DCR) was defined as the percentage of participants with a BOR of confirmed CR, confirmed PR, or SD (maintained for ≥ 16 weeks) based on RECIST v1.1.","populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","lowerLimit":"45.5","upperLimit":"70.2"},{"groupId":"OG001","value":"80.0","lowerLimit":"67.7","upperLimit":"89.2"},{"groupId":"OG002","value":"79.0","lowerLimit":"66.8","upperLimit":"88.3"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"PFS was defined as the time from randomization until the first documentation of disease progression according to RECIST v1.1 or death due to any cause, whichever occurs first","populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 54 months (through the database cutoff date of 18-Jul-2023).","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"4.0","upperLimit":"13.8"},{"groupId":"OG001","value":"21.1","lowerLimit":"10.4","upperLimit":"30.9"},{"groupId":"OG002","value":"19.8","lowerLimit":"13.6","upperLimit":"31.3"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"PFS-12 was defined as the percentage of participants who were alive and progression free at 12 months after randomization.","populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"PFS rate at 12 months after randomization.","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","lowerLimit":"24.7","upperLimit":"50.4"},{"groupId":"OG001","value":"63.5","lowerLimit":"49.2","upperLimit":"74.7"},{"groupId":"OG002","value":"73.2","lowerLimit":"59.6","upperLimit":"82.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents","description":"OS was defined as the time from the date of randomization until death due to any cause.","populationDescription":"The Intent-to-treat (ITT) population included participants who were randomized and were analyzed according to their randomized treatment group","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From time of randomization until death due to any cause. Assessed through the database cutoff date of 18-Jul-2023).","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","lowerLimit":"22.6","upperLimit":"NA","comment":"The upper limit of 95% CI could not be calculated as it was not reached."},{"groupId":"OG001","value":"NA","lowerLimit":"31.9","upperLimit":"NA","comment":"The median and upper limit of 95% CI could not be calculated as they were not reached."},{"groupId":"OG002","value":"NA","lowerLimit":"31.3","upperLimit":"NA","comment":"The median and upper limit of 95% CI could not be calculated as they were not reached."}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics of Durvalumab Alone and in Combination With Novel Agents","description":"Geometric mean serum concentrations of durvalumab (μg/mL) were reported for each time point where data warrant, as appropriate.","populationDescription":"The PK-evaluable durvalumab population included participants from the As-treated population who had a non-missing baseline PK durvalumab concentration and at least one non-missing post-baseline PK durvalumab concentration","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Micrograms per milliliter","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"51"}]}],"classes":[{"title":"Cycle 1 Day 1: End of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"46"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"318.0","spread":"199.6"},{"groupId":"OG001","value":"277.4","spread":"316.1"},{"groupId":"OG002","value":"223.7","spread":"1272"}]}]},{"title":"Cycle 2 Day 1: Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":"58.6"},{"groupId":"OG001","value":"68.0","spread":"49.9"},{"groupId":"OG002","value":"74.3","spread":"40.7"}]}]},{"title":"Cycle 7 Day 1: Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"151.6","spread":"37.7"},{"groupId":"OG001","value":"127.9","spread":"66.4"},{"groupId":"OG002","value":"176.5","spread":"45.6"}]}]},{"title":"Cycle 11 Day 1: Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"156.7","spread":"50.0"},{"groupId":"OG001","value":"146.5","spread":"91.3"},{"groupId":"OG002","value":"172.4","spread":"40.4"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics of Novel Agents in Combination With Durvalumab","description":"Geometric mean serum concentrations of oleclumab (μg/mL) and monalizumab (μg/mL) were reported for each time point where data warrant, as appropriate.","populationDescription":"The PK-evaluable oleclumab/monalizumab population included participants from the As-treated population who had a non-missing baseline PK oleclumab/monalizumab concentration and at least one non-missing post-baseline PK oleclumab/monalizumab concentration","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Micrograms per milliliter","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose and at end of infusion, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1","groups":[{"id":"OG000","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG001","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Cycle 1 Day 1: End of Infusion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"581.6","spread":"210.5"},{"groupId":"OG001","value":"160.0","spread":"286.4"}]}]},{"title":"Cycle 2 Day 1: Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"216.4","spread":"58.6"},{"groupId":"OG001","value":"102.6","spread":"39.2"}]}]},{"title":"Cycle 7 Day 1: Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124.5","spread":"109.0"},{"groupId":"OG001","value":"194.5","spread":"33.8"}]}]},{"title":"Cycle 11 Day 1: Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"132.0","spread":"166.8"},{"groupId":"OG001","value":"196.2","spread":"48.7"}]}]}]},{"type":"SECONDARY","title":"Presence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents","description":"ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.\n\nADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.","populationDescription":"The durvalumab ADA-evaluable population included participants from the As-treated population who had a non-missing baseline durvalumab ADA result and at least one non-missing post-baseline durvalumab ADA result","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1","groups":[{"id":"OG000","title":"Control Arm (Durvalumab Monotherapy)","description":"Durvalumab 1500 mg IV monotherapy Q4W"},{"id":"OG001","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG002","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"33"}]}],"classes":[{"title":"ADA positive at any visit (ADA prevalence)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"Treatment-emergent ADA positive (ADA incidence)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Treatment-induced ADA (positive post-baseline only)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"ADA positive at baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"ADA positive post-baseline and positive at baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Persistently positive","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Transiently positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Presence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab","description":"ADA prevalence was defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. ADA positive post-baseline only was also referred to as treatment-induced ADA positive. Treatment-boosted ADA was defined as baseline positive ADA titer that was boosted to a 4-fold or higher following drug administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.\n\nADA incidence (treatment-emergent ADA positive) was defined as the sum of treatment-induced ADA and treatment-boosted ADA.","populationDescription":"The oleclumab/monalizumab ADA-evaluable population included participants from the As-treated population who had a non-missing baseline oleclumab/monalizumab ADA result and at least one non-missing post-baseline oleclumab/monalizumab ADA result","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization up to 15 months after first treatment: Cycle 1 Day 1 pre-dose, Cycle 2 Day 1 pre-dose (1 month), Cycle 7 Day 1 pre-dose (6 months), Cycle 11 Day 1 pre-dose (10 months) and 15 months post Cycle 1 Day 1","groups":[{"id":"OG000","title":"Arm A (Durvalumab + Oleclumab)","description":"Durvalumab 1500 mg IV Q4W + Oleclumab 3000 mg IV (Q2W for cycles 1 and 2, then Q4W starting cycle 3)"},{"id":"OG001","title":"Arm B (Durvalumab + Monalizumab)","description":"Durvalumab 1500 mg IV Q4W + Monalizumab 750 mg IV Q2W"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"ADA positive at any visit (ADA prevalence)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Treatment-emergent ADA positive (ADA incidence)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Treatment-boosted ADA","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Treatment-induced ADA (positive post-baseline only)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"ADA positive at baseline only","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"ADA positive post-baseline and positive at baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Persistently positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Transiently positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"AEs and SAEs were collected from time of signature of informed consent up to 15 months post the first dose of study treatment","description":"Treatment-emergent adverse events (TEAEs) are defined as events present at baseline that worsen in intensity after administration of study IP or events absent at baseline that emerge after administration of study IP. All TEAEs that occurred on and after first dose up to 3 months after last dose of IP (any) were summarized.","eventGroups":[{"id":"EG000","title":"Durvalumab Monotherapy","description":"Description (Arm-group)","deathsNumAffected":27,"deathsNumAtRisk":66,"seriousNumAffected":23,"seriousNumAtRisk":66,"otherNumAffected":61,"otherNumAtRisk":66},{"id":"EG001","title":"Durvalumab + Oleclumab","description":"Description (Arm-group)","deathsNumAffected":23,"deathsNumAtRisk":59,"seriousNumAffected":20,"seriousNumAtRisk":59,"otherNumAffected":52,"otherNumAtRisk":59},{"id":"EG002","title":"Durvalumab + Monalizumab","description":"Description (Arm-group)","deathsNumAffected":24,"deathsNumAtRisk":61,"seriousNumAffected":17,"seriousNumAtRisk":61,"otherNumAffected":58,"otherNumAtRisk":61}],"seriousEvents":[{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Infected dermal cyst","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Periorbital infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Spinal cord infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Sinus arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Myopathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Meningioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Oesophageal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Glomerulonephritis membranous","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Bronchostenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Oesophagobronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pulmonary valve stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Anoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]}],"otherEvents":[{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":66},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":59},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":61}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":59},{"groupId":"EG002","numEvents":19,"numAffected":13,"numAtRisk":61}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":61}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":66},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":66},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":59},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":61}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":61}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":61}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":61}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":66},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":59},{"groupId":"EG002","numEvents":29,"numAffected":26,"numAtRisk":61}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":61}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":61}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":61}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":61}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":61}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":17,"numAffected":10,"numAtRisk":59},{"groupId":"EG002","numEvents":18,"numAffected":15,"numAtRisk":61}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":66},{"groupId":"EG001","numEvents":14,"numAffected":9,"numAtRisk":59},{"groupId":"EG002","numEvents":11,"numAffected":8,"numAtRisk":61}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":66},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":61}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":66},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":59},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":61}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":59},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":61}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":6,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":14,"numAffected":8,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":61}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":66},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":59},{"groupId":"EG002","numEvents":14,"numAffected":11,"numAtRisk":61}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":66},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":61}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":66},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":59},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":61}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":61}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":61}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":61}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":61}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":66},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":59},{"groupId":"EG002","numEvents":18,"numAffected":14,"numAtRisk":61}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":66},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":61}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":66},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":59},{"groupId":"EG002","numEvents":16,"numAffected":15,"numAtRisk":61}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":66},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":59},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":61}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":66},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":61}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome."},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca Clinical Study Information Center","email":"information.center@astrazeneca.com","phone":"1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-07-27","uploadDate":"2024-08-23T03:16","filename":"Prot_002.pdf","size":3148593},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-09-04","uploadDate":"2024-08-23T03:16","filename":"SAP_003.pdf","size":1215301}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-07-25","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D009369","term":"Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"C000709515","term":"monalizumab"}]}},"hasResults":true}